(NASDAQ: DXCM) Dexcom's forecast annual revenue growth rate of 10.07% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.45%.
Dexcom's revenue in 2026 is $4,969,200,000.On average, 32 Wall Street analysts forecast DXCM's revenue for 2026 to be $2,011,332,877,450, with the lowest DXCM revenue forecast at $1,912,841,717,785, and the highest DXCM revenue forecast at $2,086,050,308,920. On average, 32 Wall Street analysts forecast DXCM's revenue for 2027 to be $2,243,032,387,160, with the lowest DXCM revenue forecast at $2,106,805,150,995, and the highest DXCM revenue forecast at $2,378,127,541,030.
In 2028, DXCM is forecast to generate $2,507,184,922,660 in revenue, with the lowest revenue forecast at $2,288,693,039,725 and the highest revenue forecast at $2,759,639,274,445.